Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery
Key facts
- Who runs it
- Nantes University Hospital
- Where
- France31 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 330 people enrolled
- Started
- 2 Mar 2018
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW
- cardiac surgery
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Primary Mitral Regurgitation grade 3+ or 4+
- Patients in class II to IV NYHA
- Mitral valve anatomy appropriate to MitraClip® therapy and mitral valve surgery
- Adult patients judged eligible for mitral valve surgery by the local heart team but at high surgical risk defined as: age ≥ 75 years and STS score ≥ 6 % or one frailty index or one major organ system compromise or one possible procedure-specific impediment (using MVARC definitions) ; or age < 75 years and STS score > 8 % or at least one other high-risk criterion following the MVARC definitions; or age > 80 years and judged at high risk for surgery by the local heart team
- Isolated Mitral valve pathology
- If revascularization procedures are required, they must be performed more than 30 days from intervention (D0)
- Patients affiliate to social security; Non-inclusion Criteria:
- Life expectancy < 1 year due to non-cardiac conditions
- Secondary Mitral regurgitation
- Evolving endocarditis or active endocarditis or inflammatory disease in the last 3 months
- Patient who cannot tolerate procedural anticoagulation or post procedural antiplatelet regimen
- Rheumatic mitral valve disease
- Evidence of intracardiac, inferior vena cava or femoral venous thrombus
- Valve anatomy not compatible with MitraClip® implantation (cf. colum 3 table 3 page 57)
- Stroke or transient ischaemic event within 30 days before D0
- Modified Rankin Scale ≥4 disability (appendix 9)
- TAVR within 30 days before D0-Untreated, clinically significant coronary artery disease requiring revascularization
- Any percutaneous cardiovascular intervention within 30 days before D0 including ATC
- Cardiovascular surgery, or carotid surgery within 30 days before D0
- Any prior mitral valve surgery or transcatheter mitral valve procedure
- Need for any concomitant cardiac surgery including treatment of severe secondary tricuspid regurgitation in accordance with class I recommendation in 2017 ESC guidelines. Surgical treatment of mild or moderate secondary tricuspid regurgitation (Class IIa and IIb recommendations) can still be performed in the protocol according to the local heart team decison
- NYHA functional class I
- LVEF < 30%
- Primary MR grade 1 to 2
- Subjects in whom transesophageal echocardiography or transseptal catheterization are contraindicated or high-risk
- Any condition preventing the patient from completing all protocol procedures (including compliance with guidelines directed medical therapy) and follow-up visits
- Patient unable or unwilling to provide written, informed consent before study enrolment
- Pregnant or nursing women
- Vulnerable people: persons deprived of liberty; under trusteeship or under curatorship
- Participation in another trial that would interfere with this trial
Who cannot take part
- Not eligible for a MitraClip® intervention after Core Lab evaluation
- Before randomization (D-21) the patient no longer fulfills eligibility criteria (inclusion criteria and non-inclusion criteria)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of the study is to demonstrate the non-inferiority for clinical efficacy of an endovascular treatment strategy with the MitraClip® in comparison with a surgical treatment strategy in patients with severe primary mitral regurgitation judged eligible for anatomical repair with the MitraClip® or mitral valve surgery with high surgical risk.
Read full original descriptionShow less
This trial is a French and Monegasque, multicenter and randomized trial. Patients enrolled will be clinically followed for 2 years ( clinical visit at 1 month, at 6 months and 12 months, phone call at 18 months and clincial visit at 24 months).
The 2 groups in the trial
- MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW DeviceTreatment being tested
MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
Treatment: percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW
- cardiac surgeryExisting treatment, for comparison
mitral valve repair in first intervention, valve replacement if repair not feasible
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicentre and Randomized Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery
- Record updated
- 13 November 2026